Northern Trust Corp Has $71.07 Million Position in Repligen Co. (NASDAQ:RGEN)

Northern Trust Corp increased its position in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 26.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 493,713 shares of the biotechnology company's stock after buying an additional 102,011 shares during the quarter. Northern Trust Corp owned 0.88% of Repligen worth $71,065,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in RGEN. Signaturefd LLC lifted its position in shares of Repligen by 172.2% in the 4th quarter. Signaturefd LLC now owns 196 shares of the biotechnology company's stock worth $28,000 after acquiring an additional 124 shares during the period. Sava Infond d.o.o. bought a new position in Repligen in the fourth quarter worth $29,000. UMB Bank n.a. boosted its stake in Repligen by 49.1% during the fourth quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company's stock worth $48,000 after buying an additional 110 shares in the last quarter. Global Retirement Partners LLC increased its holdings in Repligen by 54.0% in the 4th quarter. Global Retirement Partners LLC now owns 368 shares of the biotechnology company's stock valued at $53,000 after buying an additional 129 shares during the period. Finally, Pilgrim Partners Asia Pte Ltd acquired a new position in shares of Repligen in the 4th quarter valued at $55,000. 97.64% of the stock is owned by institutional investors and hedge funds.

Repligen Stock Performance

Shares of Repligen stock opened at $140.92 on Tuesday. The firm has a 50 day simple moving average of $137.38 and a 200 day simple moving average of $145.84. Repligen Co. has a fifty-two week low of $102.97 and a fifty-two week high of $182.52. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76. The firm has a market cap of $7.91 billion, a P/E ratio of -276.31, a P/E/G ratio of 4.54 and a beta of 1.27.

Repligen (NASDAQ:RGEN - Get Free Report) last released its earnings results on Tuesday, April 29th. The biotechnology company reported $0.39 earnings per share for the quarter, topping analysts' consensus estimates of $0.35 by $0.04. The company had revenue of $169.17 million during the quarter, compared to the consensus estimate of $163.65 million. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. The firm's quarterly revenue was up 10.4% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.28 earnings per share. Sell-side analysts predict that Repligen Co. will post 1.72 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the stock. JPMorgan Chase & Co. lowered their target price on shares of Repligen from $200.00 to $190.00 and set an "overweight" rating on the stock in a research note on Tuesday, April 29th. Royal Bank of Canada dropped their target price on Repligen from $202.00 to $189.00 and set an "outperform" rating for the company in a report on Wednesday, April 30th. HC Wainwright restated a "buy" rating and set a $180.00 target price on shares of Repligen in a research report on Monday. Wolfe Research upgraded Repligen from a "peer perform" rating to an "outperform" rating and set a $160.00 price target on the stock in a research report on Tuesday, April 29th. Finally, TD Cowen began coverage on Repligen in a report on Monday, February 10th. They set a "buy" rating and a $200.00 price objective for the company. Six equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $173.25.

Insider Activity

In other Repligen news, Director Margaret Pax acquired 250 shares of the business's stock in a transaction that occurred on Monday, March 17th. The shares were acquired at an average cost of $150.69 per share, for a total transaction of $37,672.50. Following the completion of the acquisition, the director now directly owns 1,043 shares of the company's stock, valued at approximately $157,169.67. This represents a 31.53 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 1.20% of the company's stock.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Co. (NASDAQ:RGEN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.